List view / Grid view
2 July 2015 | By Victoria White
Gilead Sciences has submitted a NDA to the FDA for an investigational, once-daily single tablet regimen for the treatment of HIV-1 infection...
18 June 2015 | By Victoria White
NICE has opened a consultation on preliminary draft guidance for the drug idelalisib (Zydelig) for adults with chronic lymphocytic leukaemia...
1 June 2015 | By Victoria White
Results from a study of idelalisib in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukaemia have been announced...
29 May 2015 | By Victoria White
Gilead’s MAA for a fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) has been fully validated and is now under evaluation by the EMA..
28 May 2015 | By Victoria White
Top line results have been announced from the GS-4774 Phase 2 study in patients with HBV on long term viral suppression with an oral antiviral treatment...
23 April 2015 | By Victoria White
Results announced from several Phase 2 clinical studies evaluating uses of Harvoni and other Sovaldi-based regimens for the treatment of HCV infection...
8 April 2015 | By Victoria White
Gilead has submitted a NDA to the FDA for an investigational fixed-dose combination of F/TAF for the treatment of HIV-1 infection...
9 March 2015 | By Gilead Sciences
New oral treatment for Chronic Lymphocytic Leukaemia now approved for use within NHS Scotland...
27 February 2015 | By Gilead Sciences
96 percent SVR12 rate for hepatitis C genotypes 1 and 4 among HIV-infected patients on antiretroviral therapy...
27 February 2015 | By Gilead Sciences
First TAF-based regimen found to be non-inferior with improved renal and bone parameters compared to stribild®...
10 February 2015 | By Doctors of the World
Doctors of the World - Médecins du Monde is today filing its opposition to the patent granted for sofosbuvir (Sovaldi) with the European Patent Office...
11 December 2014 | By Gilead Sciences
Results describing long-term safety and disease control presented at the 56th American Society of Hematology Annual Meeting...
13 November 2014 | By Gilead Sciences
High cure rates in nearly 800 Hepatitis C Virus (HCV patients with advanced liver disease)...
22 October 2014 | By GlobalData
The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to maintain its dominance in an increasingly competitive market...
8 October 2014 | By GlobalData
Gilead’s announcement of positive Phase III results for its investigational single-tablet regimen (STR), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (TAF), caps a series of developments bolstering the company’s position as HIV treatment market leader...
